122 related articles for article (PubMed ID: 28581488)
1. Osteoblast-derived Laminin-332 is a novel negative regulator of osteoclastogenesis in bone microenvironments.
Uehara N; Kukita A; Kyumoto-Nakamura Y; Yamaza T; Yasuda H; Kukita T
Lab Invest; 2017 Oct; 97(10):1235-1244. PubMed ID: 28581488
[TBL] [Abstract][Full Text] [Related]
2. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
3. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
4. Pueraria lobate Inhibits RANKL-Mediated Osteoclastogenesis Via Downregulation of CREB/PGC1β/c-Fos/NFATc1 Signaling.
Park KH; Gu DR; Jin SH; Yoon CS; Ko W; Kim YC; Lee SH
Am J Chin Med; 2017; 45(8):1725-1744. PubMed ID: 29121799
[TBL] [Abstract][Full Text] [Related]
5. 2E-Decene-4,6-diyn-1-ol-acetate inhibits osteoclastogenesis through mitogen-activated protein kinase-c-Fos-NFATc1 signalling pathways.
Park YR; Su XD; Shrestha SK; Yang SY; Soh Y
Clin Exp Pharmacol Physiol; 2022 Mar; 49(3):341-349. PubMed ID: 34729812
[TBL] [Abstract][Full Text] [Related]
6. The natural flavonoid galangin inhibits osteoclastic bone destruction and osteoclastogenesis by suppressing NF-κB in collagen-induced arthritis and bone marrow-derived macrophages.
Huh JE; Jung IT; Choi J; Baek YH; Lee JD; Park DS; Choi DY
Eur J Pharmacol; 2013 Jan; 698(1-3):57-66. PubMed ID: 22985747
[TBL] [Abstract][Full Text] [Related]
7. DOK3 Modulates Bone Remodeling by Negatively Regulating Osteoclastogenesis and Positively Regulating Osteoblastogenesis.
Cai X; Xing J; Long CL; Peng Q; Humphrey MB
J Bone Miner Res; 2017 Nov; 32(11):2207-2218. PubMed ID: 28650106
[TBL] [Abstract][Full Text] [Related]
8. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
9. Emodin regulates bone remodeling by inhibiting osteoclastogenesis and stimulating osteoblast formation.
Kim JY; Cheon YH; Kwak SC; Baek JM; Yoon KH; Lee MS; Oh J
J Bone Miner Res; 2014 Jul; 29(7):1541-53. PubMed ID: 25832436
[TBL] [Abstract][Full Text] [Related]
10. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
[TBL] [Abstract][Full Text] [Related]
11. Interleukin 29 inhibits RANKL-induced osteoclastogenesis via activation of JNK and STAT, and inhibition of NF-κB and NFATc1.
Peng Q; Luo A; Zhou Z; Xuan W; Qiu M; Wu Q; Xu L; Kong X; Zhang M; Tan W; Xue M; Wang F
Cytokine; 2019 Jan; 113():144-154. PubMed ID: 30001863
[TBL] [Abstract][Full Text] [Related]
12. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
13. (2S)-2'-Methoxykurarinone inhibits osteoclastogenesis and bone resorption through down-regulation of RANKL signaling.
Kim JY; Kim JY; Kim JJ; Oh J; Kim YC; Lee MS
Biol Pharm Bull; 2014; 37(2):255-61. PubMed ID: 24492722
[TBL] [Abstract][Full Text] [Related]
14. G protein-coupled receptor 84 controls osteoclastogenesis through inhibition of NF-κB and MAPK signaling pathways.
Park JW; Yoon HJ; Kang WY; Cho S; Seong SJ; Lee HW; Yoon YR; Kim HJ
J Cell Physiol; 2018 Feb; 233(2):1481-1489. PubMed ID: 28574596
[TBL] [Abstract][Full Text] [Related]
15. Arctigenin inhibits osteoclast differentiation and function by suppressing both calcineurin-dependent and osteoblastic cell-dependent NFATc1 pathways.
Yamashita T; Uehara S; Udagawa N; Li F; Kadota S; Esumi H; Kobayashi Y; Takahashi N
PLoS One; 2014; 9(1):e85878. PubMed ID: 24465763
[TBL] [Abstract][Full Text] [Related]
16. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC
Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379
[TBL] [Abstract][Full Text] [Related]
17. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory activity of linarin on osteoclastogenesis through receptor activator of nuclear factor κB ligand-induced NF-κB pathway.
Wang J; Fu B; Lu F; Hu X; Tang J; Huang L
Biochem Biophys Res Commun; 2018 Jan; 495(3):2133-2138. PubMed ID: 29269297
[TBL] [Abstract][Full Text] [Related]
19. Dual Role of Cyanidin-3-glucoside on the Differentiation of Bone Cells.
Park KH; Gu DR; So HS; Kim KJ; Lee SH
J Dent Res; 2015 Dec; 94(12):1676-83. PubMed ID: 26350961
[TBL] [Abstract][Full Text] [Related]
20. Selective signaling by Akt1 controls osteoblast differentiation and osteoblast-mediated osteoclast development.
Mukherjee A; Rotwein P
Mol Cell Biol; 2012 Jan; 32(2):490-500. PubMed ID: 22064480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]